# **Welcome Investors**

#### September 2024







### **Forward Looking Statements**

Certain statements in this presentation may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may be identified by words such as "may," "should," "expect," "intend," "will," "estimate," "anticipate," "believe," "predict," or similar words. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements include, among other things, statements regarding: the Company's prospects, anticipated advantages the Company expects to realize from its acquisition strategies, the Company's financial performance, targets, goals, and metrics, the Company's revenue, gross margin and operating margin targets, participation in multiple markets, its engineering and product development resources, the benefits of the Company's product development business (including its margin and customer relationship), the Company's business opportunities and competitive advantages, the Company's growth potential and strategies for growth, and statements about customer and industry demand.

Investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including without limitation risks associated with the identification of suitable acquisition candidates and the successful, efficient execution of acquisition transactions and integration of any such acquisition candidates, economic conditions that affect sales of the products of the Company's customers, adverse changes in general economic and geopolitical conditions, including, without limitation, global supply chain disruptions, labor cost increases and inflation, the ongoing conflict between Russia and Ukraine, other similar conflicts and civil unrest in Haiti, which is in proximity to our manufacturing facilities in the Dominican Republic, could have a material adverse effect on our business and results of operations, the ability of the Company to obtain new customers, the ability of the Company to fulfill its obligations on long-term contracts and to retain current customers, particularly our customer who accounted for more than 28% of our revenue for 2023, the ability of the Company to maintain and grow its current margins, the ability of the Company to achieve its revenue, gross margin and operating margin targets, the Company with the Securities and Exchange Commission ("SEC"). Accordingly, actual results may differ materially. The risks and uncertainties included above are not exhaustive. Readers are referred to the documents filed by the Company with the SEC, specifically the last reports on Forms 10-K and 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company's expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company's expressly disclaims or any change in events, conditions or circumstances on which any such statement is based.

#### Use of Non-GAAP Financial Measures


This presentation includes non-generally accepted accounting principles ("GAAP") performance measures. The Company uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results. The Company's management believes these non-GAAP measures are useful in evaluating the Company's operating performance and are similar measures reported by publicly listed U.S. competitors, and regularly used by securities analysts, institutional investors, and other interested parties in analyzing operating performance and prospects. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. By providing these non-GAAP measures, the Company's management intends to provide investors with a meaningful, consistent comparison of the Company's performance for the periods presented. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company's definition of these non-GAAP measures may differ from similarly titled measures of performance used by other companies in other industries or within the same industry.



# Who We Are



UFP Technologies is an innovative designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products.



1. As of 9/23/2024 2. Pro-forma revenue includes recent acquisitions

3



### **Shaping Innovation**

We help our customers develop, improve, manufacture, or protect their products through:



### **Design & engineering capabilities**



#### **Materials expertise**



### **Precision manufacturing**



#### **Strategic locations**





# **Our Process**

Innovative process from design and engineering to manufacturing and delivery



#### Proprietary and Tested Technology Integration






## **Product Development Business**




We bring deep experience in flexible material-based device manufacturing, from components and packaging, to final device assembly



### **Primary Focus Areas**





# MedTech




### **\$518 billion, 6.3% CAGR<sup>1</sup>** Global Medical Device Market

Customers include 26 of the top 30 largest medical device manufacturers in the world<sup>2</sup>

#### • Applications Expertise

- Robotic Surgery Drapes
- Orthopedic Sterile Packaging
- Catheter & Guidewire Sterile Packaging
- IV Port Cleaners
- Surgical Site Preparation
- Minimally Invasive Surgery Ports
- Negative Pressure Wound Therapy
- MedSurg Beds

#### MedTech Revenue By Segment<sup>3</sup>



- 1. Fortune Business Insights \$518 billion as of 2023. 6.3% CAGR for a forecast period of 2024-2032.
- 2. Medical Design & Outsourcing 2024 MedTech Big 100.
- 3. Proforma annual mix of revenue as of 8/21/2024, which includes revenue from the acquisitions of Welch Fluorocarbon, Inc., Marble Medical, Inc., AJR Enterprises, LLC and AQF Limited

### MedTech Portfolio





## **Advanced Components**

**I AEROSPACE & DEFENSE AUTOMOTIVE** Ĩ **INDUSTRIAL** 

#### 

**Highly engineered** components and packaging used in targeted large and growing niches

#### 

Our products are present on many of the world's leading brands including GM, Ford, Mercedes, Tesla, Boeing and **Lockheed Martin** 

### **UFP Differentiation**



Innovative design engineering



- Material expertise 3



- **Complex laminated composites**
- Dedicated in house tooling & equipment manufacturing 5

#### AS9100 certified 6



### **Advanced Components Portfolio**



### **Growth Strategy**





Internal Growth: Market To Our Sweet Spot

**Strategic Acquisitions** 



# Organic Growth Opportunity



#### Market to our sweet spot and differentiated capabilities

- » Leverage technology differentiation
- » Engineering resources
- » Exclusive access to specialty materials
- » Scale (footprint, clean room manufacturing)



#### **Expand business with existing customers**

- » Offer complementary products and services
- » Additional value-add services



#### Focus on high growth niche segments (MedTech – approximately 90% of revenue and growing)

- » Single-use, single-patient
- » Customer funded development





### Acquisition Growth Opportunity



#### **Continue to Focus on Higher-Growth, Higher-Margin MedTech Opportunities that Create Value**

- » Become more valuable to our customers
- » Strategic focus new capability, geography, growing market segment, materials
- » Add scale
- » Look for synergistic opportunities
- » Cultural fit

Goal is for acquisitions to be accretive within the first year.

Experienced and disciplined management team with 19 acquisitions completed





- Location:
  Dover, NH
- Associates: 83
- Acquired July 16, 2024

#### Key Markets Served

- Medical
- o Pacemaker
- Cardiac Defibrillator
- Cardiac Monitor
- Neuromodulator
- Advanced Material Products

#### **Key Materials**

- Films
- Textiles

### Thin Film Molding for Implantable Medical Devices





#### **Products & Services**

- Micro thermoforming of thin gauge specialty films
- EMI shielding and insulations for implantable devices
- High temperature films (+500)
- Low temperature films (-400)



- Thermoforming (small parts)
- Heat Sealing
- Clean Room Assembly
- Tooling Development
- Ability to Automate



- Locations:
- St. Charles, Illinois
- Santiago, Dom Rep
- Associates: 700
- Acquired July 1, 2024

#### Key Market Served

- Safe patient handling
- Patient transfer
- Patient Comfort

#### **Key Materials**

- Engineered textiles
  - $\circ$  2 directional

Single use safe patient handling systems



#### **Products & Services**

- Single patient medical solutions
- Low-cost manufacturing
- Specialty fabrics expertise in converting and assembly





- Complex cut and sew work cells
- Final packaging, kitting, and distribution



- Location:
- o Tallahassee, FL
- Associates: 25
- Acquired June 24, 2024


#### Key Markets Served

- Stick to skin applications
- Biocompatible tapes and adhesives
- RAS drapes

#### **Key Materials**

- Medical grade tapes
- Positioning labels
- Specialty adhesives

3M Healthcare adhesive converter with high-speed die-cutting and converting expertise







#### **Products & Services**

- Multi-layered laminates with specialty adhesives
- High speed die-cutting
- Product assembly
- Custom packaging



- Rotary die cutting
- Flexographic printing
- Controlled environment mfg.



- Locations:
- Navan, Ireland
- Singapore
- Associates: 50
- Acquired August 23, 2024

#### Key Markets Served

- Orthopedics
- Wound care
- Infection Prevention

Foam & flexible thermoplastic polyurethane (TPU) solutions for use in a wide range of medical devices.







#### **Products & Services**


- Sterile packaging components
- Die cut medical parts
- Cleanroom assembly



- Rotary die cutting
- RF welding
- Cleanroom fabrication

## Locations





# Why Invest?





ы	<b>'//</b>		<b>A</b> <b>3 3 3</b>		(\$)
Significant market growth opportunities	<b>Barriers</b> to entry	Strong customer relationships	Experienced management team	Proven growth strategy	Attractive financial metrics



### Significant Market Growth Opportunities



# Focused on fast growing segments



### **Market Focused On**

- » Better Patient Outcomes
- » Infection Prevention
- » Reducing Healthcare Costs



### **Global Footprint**


» Bringing New Opportunities





#### Engineering Resources

 » Veteran engineering team for product design and development; more than 100 members of the engineering group



#### » Exclusive access to several specialty medical grade materials

- » Offers broad array of materials to meet customer needs
- » Over 60 years in business and strong supplier relationships/partnerships



» In-house custom equipment manufacturing capabilities



#### Intellectual Property

- » Numerous patents relating to foam, packaging, tool control, radio frequency welding, automotive super-forming processes, and other products
- » Significant manufacturing knowhow



#### Systems

- » Advanced systems (extensive quality certifications)
- In addition to existing equipment, engineers will design product specific innovations in order to meet customer needs



 » Global footprint – competition is generally smaller companies that have limited resources and access to materials

### Management Team





**R. Jeffrey Bailly** *Chairman & CEO* 

36-year history at the company



**Ronald Lataille** CFO, Sr. VP & Treasurer

27-year history at the company



Mitchell Rock President

30-year history at the company.



**Chris Litterio** SVP, Human Resources & General Counsel

Former Managing Partner and head of employment law at a major Boston law firm; 7-years at the company



Steve Cardin VP & COO, MedTech

28 years in the medical device industry; 5-years at the company



Jason Holt CCO

Former VP & GM at ITW; 6-years at the company

### **Creating Shareholder Value**

# Proven Growth Strategy



## **Financial Targets**

 $\bigstar$ 





# **Financial Targets**






### Revenue

í

12% to 18% Targeted Revenue Growth Internal Growth + Acquisitions



27

### Gross Profit Margin

í

#### Gross Margin Target - 28% to 31%

Operating Leverage from Mix Shift + Acquisition synergies + Efficiencies



28

### Adjusted\* Operating Margin

### **Operating Margin Target - 15% to 18%**


Operating leverage from mix shift + acquisition synergies + efficiencies



<sup>\*</sup>See non-GAAP reconciliation on slide 32

### í.

UFP Historical Stock Performance 20 Years



\*Measured as the percent increase from September 20, 2004 through September 20, 2024.



R. Jeffrey Bailly Chairman, CEO & President Newburyport, Massachusetts

Ronald Lataille CFO, Sr. VP & Treasurer Newburyport, Massachusetts



Newburyport, MA 01950 978-352-2200 investorinfo@ufpt.com







# Appendix



#### **Reconciliation of Non-GAAP Results**

(in Millions)		2019		2020		2021		2022		2023		Q2 2024 YTD	
Revenue, As Reported	\$	198.4	\$	179.4	\$	206.3	\$	354.0	\$	400.1	\$	215.2	
Operating Income, as reported		24.7		16.7		21.2		55.4		55.7		33.9	
Add: Acquisition/ Restructuring related Costs		-		-		0.4		1.0		-		0.9	
Add earnout fair value adjustment		-		-		-		9.8		3.5		0.5	
Less: Gain or Add: Loss on Sale of fixed assets		-		0.5		-		(6.1)		0.1		0.7	
Less: Sale of MFT		-		-		-		(15.6)		-		-	
Adjusted Operating Income	\$	24.7	\$	17.2	\$	21.6	\$	44.5	\$	59.3	\$	36.0	
Adjusted Operating Margin		12.4%		9.6%		10.5%		12.6%		14.8%		16.7%	